WebApr 24, 2024 · Drug: RC48-ADC: Masking: None (Open Label) Primary Purpose: Treatment: Official Title: A Multicenter, Open Label,Single Arm,Phase II Study to Evaluate the … WebUrothelial carcinoma represents one of the most prevalent types of cancer worldwide, and its incidence is expected to grow. Although the treatment of the advanced disease was …
Urothelial Carcinoma, HER2-expressing Trial in Beijing (RC48-ADC ...
WebDec 2, 2024 · In this single-arm, phase II trial of 43 Chinese patients with HER2-positive urothelial carcinoma (IHC status 3+ or 2), the majority of whom had only received one line … WebNov 15, 2024 · Keywords: urothelial carcinoma, human epidermal growth factor receptor 2 (HER2),trastuzumab (herceptin), pembrolizumab, antibody-drug conjugates, RC48-ADC. … on the banks of the ohio
RC48-ADC appeared on ASCO 2024 meeting again and ... - ADC …
WebApr 11, 2024 · 3.Open-label, Multicenter, Phase II Studyof RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with LocallyAdvanced or Metastatic Urothelial Carcinoma. Clin Cancer Res 2024;27:43–51. 4.《科伦博泰TROP2-ADC 新药SKB264联合PD-L1单抗KL-A167治疗非小细胞肺癌II期临床获批开展》,科伦E药,2024-04-02. WebUrothelial carcinoma is cancer that starts in your urothelium, the tissue that lines parts of your urinary system. Urothelial carcinoma accounts for about 90% of all cases of bladder cancer and 7% of all cases of kidney cancer, including cancer in your renal pelvis and ureter. Bladder and kidney cancers caused by urothelial carcinoma have ... WebHere, we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer. Methods: … on the banks of the old raritan